Compounds for the treatment of acute brain injury

Unique Selling Points
- Brain-permeable neuroprotective small-molecule compound
- Effective when administered up to 12 hours after the injury
- Novel targeted mechanism-of-action (first-in-class)

Commercial Perspectives
Acute brain injury is a major world-wide health issue with very limited medical treatment options. It includes traumatic brain injury (caused by, for example, road accidents or a blow to the head) and ischemic stroke. Uniquely, our compound can be given hours after the injury.

Technology Description
Cmpd A rapidly enters the brain after systemic administration and targets an intracellular, multi-functional enzyme involved in higher brain functions via a novel binding site.

Current State
Cmpd A: Proof-of-concept in several brain injury models. A scale-up synthesis use has been developed. Prodrug design is ongoing.
2nd generation compounds: In vitro studies to select candidates for in vivo testing and further mechanism-of-action studies.

The inventors
Petrine Wellendorph, Bente Frølund, Anders Klein, Ulrike Leurs, Rasmus Clausen, Andrew Clarkson, Joshua Houlton

Contact Information
Liv Søndergaard Thomsen
TTO Manager; +45 35 32 53 67
Liv.thomsen@adm.ku.dk

Seeking
- Funding/investors
- Licensee
- Partner/research collaboration

Patent application filed 02 Feb 2018

Biotech and Pharma